Cwm LLC Raises Stock Position in Danaher Co. (NYSE:DHR)

Cwm LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,113 shares of the conglomerate’s stock after purchasing an additional 45 shares during the period. Cwm LLC’s holdings in Danaher were worth $4,422,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of DHR. Wellington Management Group LLP raised its stake in Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares during the period. Allen Investment Management LLC raised its stake in shares of Danaher by 1,440.7% in the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after acquiring an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $178,850,000. Alecta Tjanstepension Omsesidigt purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $161,994,000. Finally, Harris Associates L P raised its stake in shares of Danaher by 27.7% in the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after acquiring an additional 642,759 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Royal Bank of Canada boosted their price target on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and upped their target price for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, KeyCorp upped their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $268.27.

Danaher Trading Up 7.2 %

NYSE DHR opened at $253.11 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The stock has a market capitalization of $187.44 billion, a PE ratio of 39.61, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. The firm has a 50 day moving average of $248.95 and a two-hundred day moving average of $230.64.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the previous year, the business posted $2.87 EPS. The firm’s revenue was down 10.2% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 16.90%.

Insiders Place Their Bets

In other news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock worth $8,265,802 in the last 90 days. Corporate insiders own 10.90% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.